CN101460851B - 与二肽基肽酶有关的疾病状态的诊断和预后 - Google Patents

与二肽基肽酶有关的疾病状态的诊断和预后 Download PDF

Info

Publication number
CN101460851B
CN101460851B CN200780016051.1A CN200780016051A CN101460851B CN 101460851 B CN101460851 B CN 101460851B CN 200780016051 A CN200780016051 A CN 200780016051A CN 101460851 B CN101460851 B CN 101460851B
Authority
CN
China
Prior art keywords
dpp
activity
distinguishable
subtypes
parameter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200780016051.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN101460851A (zh
Inventor
P·奥姆兰
C·A·捷尔芬德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Becton Dickinson and Co
Original Assignee
Becton Dickinson and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson and Co filed Critical Becton Dickinson and Co
Publication of CN101460851A publication Critical patent/CN101460851A/zh
Application granted granted Critical
Publication of CN101460851B publication Critical patent/CN101460851B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CN200780016051.1A 2006-03-13 2007-03-13 与二肽基肽酶有关的疾病状态的诊断和预后 Active CN101460851B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US78192406P 2006-03-13 2006-03-13
US60/781,924 2006-03-13
US80439706P 2006-06-09 2006-06-09
US60/804,397 2006-06-09
US89276707P 2007-03-02 2007-03-02
US60/892,767 2007-03-02
PCT/US2007/006653 WO2007106595A1 (en) 2006-03-13 2007-03-13 Diagnosis and prognosis of dipeptidyl peptidase-associated disease states

Publications (2)

Publication Number Publication Date
CN101460851A CN101460851A (zh) 2009-06-17
CN101460851B true CN101460851B (zh) 2016-09-21

Family

ID=38265130

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780016051.1A Active CN101460851B (zh) 2006-03-13 2007-03-13 与二肽基肽酶有关的疾病状态的诊断和预后

Country Status (11)

Country Link
US (1) US8652789B2 (https=)
EP (1) EP1994415B9 (https=)
JP (1) JP5410955B2 (https=)
KR (1) KR101376471B1 (https=)
CN (1) CN101460851B (https=)
AU (1) AU2007225054B2 (https=)
BR (1) BRPI0708900A2 (https=)
CA (1) CA2645302C (https=)
ES (1) ES2549860T3 (https=)
MX (1) MX2008011665A (https=)
WO (1) WO2007106595A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527649T3 (es) * 2007-12-10 2015-01-28 F. Hoffmann-La Roche Ag Panel de marcadores para el cáncer colorrectal
ES2533428T3 (es) * 2009-05-04 2015-04-10 F. Hoffmann-La Roche Ag Uso de DPPIV/Seprasa como un marcador para el cáncer
JP6065172B2 (ja) * 2010-10-22 2017-01-25 国立大学法人名古屋大学 微小血管障害又はその関連疾患のバイオマーカー
US20140273008A1 (en) * 2013-03-15 2014-09-18 Molecular Bioproducts, Inc. Methods to assess enzyme activity using mass spectrometric immunoassay
EP3314004A1 (en) * 2015-06-26 2018-05-02 DuPont Nutrition Biosciences ApS Aminopeptidases for protein hydrolyzates
AU2017252212B2 (en) * 2016-04-21 2023-09-07 4TEEN4 Pharmaceuticals GmbH Methods for determining DPP3 and therapeutic methods
CN110426518A (zh) * 2019-07-19 2019-11-08 宁波熙宁检测技术有限公司 一种定量检测人类血浆中dpp-4酶活性的方法
EP4308937B1 (en) * 2021-03-16 2026-02-04 Astrazeneca AB System and method for online detection of a post-translational modification of a polypeptide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004104216A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900662A (en) 1987-07-21 1990-02-13 International Immunoassay Laboratories, Inc. CK-MM myocardial infarction immunoassay
US5382515A (en) 1987-07-21 1995-01-17 International Immunoassay Laboratories, Inc. Creative kinase-MB immunoassay for myocardial infarction and reagents
US5382522A (en) 1987-07-21 1995-01-17 International Immunoassay Laboratories, Inc. Immunoassay for creatine kinase-MB and creatine kinase-BB isoforms and reagents
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004104216A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Diagnostic significance of urinary enzymes for diabetes mellitus and hypertension;Ishii Naohito et al;《Biosis》;19951231;全文 *
Hyperglycaemmia increases dipeptidyl peptidase IV activity in diabetes mellitus;Mannucci E et al;《DIABETOLOGIA》;20050630;第48卷(第6期);1168-1172 *

Also Published As

Publication number Publication date
JP2009529884A (ja) 2009-08-27
AU2007225054A1 (en) 2007-09-20
CA2645302A1 (en) 2007-09-20
US8652789B2 (en) 2014-02-18
EP1994415B9 (en) 2015-12-16
ES2549860T3 (es) 2015-11-02
KR101376471B1 (ko) 2014-03-27
CA2645302C (en) 2017-07-11
JP5410955B2 (ja) 2014-02-05
EP1994415B1 (en) 2015-07-29
WO2007106595A1 (en) 2007-09-20
AU2007225054B2 (en) 2012-08-16
MX2008011665A (es) 2008-10-08
KR20090008218A (ko) 2009-01-21
EP1994415A1 (en) 2008-11-26
US20070264671A1 (en) 2007-11-15
CN101460851A (zh) 2009-06-17
BRPI0708900A2 (pt) 2011-06-14

Similar Documents

Publication Publication Date Title
CN101460851B (zh) 与二肽基肽酶有关的疾病状态的诊断和预后
US20210139946A9 (en) Compositions and methods for diagnosis of shock
Javors et al. Current status of carbohydrate deficient transferrin, total serum sialic acid, sialic acid index of apolipoprotein J and serum β‐hexosaminidase as markers for alcohol consumption
WO2004076679A2 (en) Serum macrophage migration inhibitory factor (mif) as marker for prostate cancer
KR20150084802A (ko) 진단 장치 및 방법
US20070087448A1 (en) Biological profiles and methods of use
EP2757377A1 (en) Method for detecting pancreatic disease marker
Yang et al. The prognostic value of serum α-klotho in age-related diseases among the US population: a prospective population-based cohort study
Iwata et al. Identification of diabetic nephropathy in patients undergoing kidney biopsy through blood and urinary profiles of d-serine
Najafi et al. Assessment of serum and urine neurophil gelatinase-associated lipocalin (s-NGAL and u-NGAL) level as a predictive factor of disease progression in diabetic nephropathy in type 2 DM
JP2013534315A (ja) ｃ−Ｓｒｃ選択反応モニタリングアッセイ
JP3677210B2 (ja) 前立腺がんを診断し、モニターし、そして病期決定する新規な方法
WO2012088105A2 (en) Methods and compositions for predicting disease status in cancer
Goetze et al. Impact of assay epitope specificity in gastrinoma diagnosis
US20080213800A1 (en) Method for Examing Interstitital Cystitis
AL-khaykanee et al. A review about liver function tests
RU2000119129A (ru) Молекула днк, кодирующая мутантный препронейропептид y, мутантный сигнальный пептид и их применения
US20120115177A1 (en) Compositions and Methods for Diagnosis of Shock
CN119555940B (zh) 一种与肿瘤骨转移及疼痛相关的血浆多肽标志物col1a2及应用
Shaligram et al. Standard of care in diagnosis of diabetes mellitus: HbA1c
TWI498564B (zh) 用以評估腫瘤增生、侵犯或轉移風險之生物標記及方法
Smith et al. Performance Comparison of RaDaR 1.0 and RaDaR ST Assays for Circulating Tumor DNA Detection Across Solid Tumor Types
Mahmood et al. Evaluation of zinc alpha 2-glycoprotein as threshold infertility concept in women with polycystic ovarian syndrome.
CN116068205A (zh) 一种糖链标志物检测alt正常的慢性乙型肝炎患者肝硬化的检测试剂、使用方法及应用
CN118028093A (zh) 一种心肌梗死标志物的检测装置

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant